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Abstract
Background: Determinations of thyrotropin (TSH) and free thyroxine (FT4) represent the gold standard in evaluation
of thyroid function. To screen for novel peripheral biomarkers of thyroid function and to characterize FT4-associated
physiological signatures in human plasma we used an untargeted OMICS approach in a thyrotoxicosis model.
Methods: A sample of 16 healthy young men were treated with levothyroxine for 8 weeks and plasma was sampled
before the intake was started as well as at two points during treatment and after its completion, respectively. Mass
spectrometry-derived metabolite and protein levels were related to FT4 serum concentrations using mixed-effect linear
regression models in a robust setting. To compile a molecular signature discriminating between thyrotoxicosis and
euthyroidism, a random forest was trained and validated in a two-stage cross-validation procedure.
Results: Despite the absence of obvious clinical symptoms, mass spectrometry analyses detected 65 metabolites and
63 proteins exhibiting significant associations with serum FT4. A subset of 15 molecules allowed a robust and good
prediction of thyroid hormone function (AUC = 0.86) without prior information on TSH or FT4. Main FT4-associated
signatures indicated increased resting energy expenditure, augmented defense against systemic oxidative
stress, decreased lipoprotein particle levels, and increased levels of complement system proteins and
coagulation factors. Further association findings question the reliability of kidney function assessment under
hyperthyroid conditions and suggest a link between hyperthyroidism and cardiovascular diseases via increased
dimethylarginine levels.
Conclusion: Our results emphasize the power of untargeted OMICs approaches to detect novel pathways of
thyroid hormone action. Furthermore, beyond TSH and FT4, we demonstrated the potential of such analyses
to identify new molecular signatures for diagnosis and treatment of thyroid disorders. This study was
registered at the German Clinical Trials Register (DRKS) [DRKS00011275] on the 16th of November 2016.
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Background
Thyroid hormones (TH) circulating as thyroxine (T4) and
triiodothyronine (T3) are essential for normal development
and function of virtually all tissues [1]. Both their synthesis
and release are closely controlled by pituitary thyroid
stimulating hormone (TSH), which in turn is stimulated by
hypothalamic thyrotropin releasing hormone (TRH). TH
exert a negative feedback on synthesis and secretion of
TRH as well as of TSH. As the feedback of TH on the
hypothalamic-pituitary regulation of TSH is particularly
sensitive, the robust relation of TSH and free T4 (FT4) is
generally used as the ‘gold standard’ tool for diagnosis and
follow-up of thyroid disorders.
Specific TH transporters mediate the cellular uptake of
TH [2]. At the latest in the target cells, specific deiodi-
nases convert T4 to T3 which is the major ligand for the
nuclear TH receptors (TR) α and β and their subtypes [1].
Formation of ligand-activated TR homodimers and het-
erodimers with TR auxiliary proteins and other receptors,
such as retinoid X receptor (RXR), finally results in stimu-
lated or repressed expression of TH target genes. In
addition to this so-called genomic action mediated by nu-
clear TRs, TH exert rapid non-genomic effects by binding
to extranuclear receptors, like truncated cytoplasmic TRα
isoforms or plasma membrane-localized integrin ανβ3,
resulting in the activation of specific phosphorylation cas-
cades [3]. Also, for the putative TH derivative 3,5-diio-
dothyronine, interaction with specific mitochondrial sites
was reported [3]. Thus, in sum, by cell- and organ-specific
TH uptake and activation, TR subtype synthesis and non-
genomic modulation, TH are able to induce their various
tissue- and cell-specific responses. It is thus not surprising
that clinical symptoms of thyroid dysfunction are regarded
to be of restricted diagnostic value because they are nei-
ther sufficiently sensitive nor specific [4]. Currently, the
diagnosis of thyroid dysfunction and the assessment of
treatment effects are almost entirely based on the bio-
chemical determination of serum TSH, free T4 (FT4) and,
under special conditions, free T3 (FT3). However, their use
is limited by a number of drawbacks.
Despite the sensitive negative feedback regulation be-
tween TSH and FT4 leading to a tightly controlled indi-
vidual set point [5, 6], large population-based studies
established a wide reference range for TSH and free TH
levels. This is explained by varying sensitivity at different
levels of the activation process as well as the negative
feedback mechanisms [7] and differences between assay
specificities [8, 9]. Additionally, a number of rare severe
clinical conditions lead to discordant alterations in serum
TSH and FT4, including resistance to TH, TSH producing
pituitary tumors, or central hypothyroidism [10, 11].
Therefore, peripheral biomarkers such as cholesterol and
sex hormone- binding globulin (SHBG) concentrations
have been suggested under these conditions as they are
strongly correlated with thyroid function [12, 13].
However, because these parameters are also influenced by
non-thyroidal disturbances, they were never established in
clinical practice and accordingly current guidelines do not
recommend their use [14]. Thus, currently available
diagnostic tools are insufficient and novel biomarkers are
urgently needed.
Indeed, systematic screens for novel markers of thyroid
function in humans are lacking so far. In particular, only
few studies attempted to detect peripheral TH effects by
untargeted approaches. The influence of thyroid dysfunc-
tion on various tissue-specific proteomes or the metabo-
lomes of serum and urine was assessed almost entirely
using rodent models [15–18]. Even if these studies un-
doubtedly added to our understanding of TH action on
metabolism, translation of these results to humans is still
missing. Moreover, most of the scarce data on peripheral
TH effects in humans are based on observations in patients
with thyroid disorders such as autoimmune thyroid disease,
which hamper the distinction between TH dependent
effects and those related to the underlying autoimmune
process. To avoid these problems, we herein studied TH
effects in a strictly controlled model of experimental hyper-
thyroidism where healthy young male volunteers were sub-
jected to a challenge of thyroxine over a period of 8 weeks.
Untargeted plasma proteome and metabolome analyses
were performed in a hypothesis-free approach to detect
FT4-associated proteins and metabolites, and the generated
data were used for characterization of main physiological
signatures and to develop a biomarker-based classification
model that allows prediction of TH function without prior
information on TSH or free TH.
Methods
Study design and sampling
Sixteen young healthy male subjects were treated with a
single tablet of 250 μg levothyroxine (L-T4; Henning-Berlin,
Berlin, Germany) per day for 8 weeks. Plasma was sampled
before L-T4 intake started (baseline, bas), after 4 (w4(T4))
and 8 (w8(T4)) weeks under treatment as well as 4 (w12)
and 8 (w16) weeks after ending the application, respectively
(Fig. 1a). The chosen sample size is appropriate as the
volunteers were selected to reduce inter-individual variance.
The repeated measure character of the study further re-
duced the influence of inter-individual variance. Body mass
index (BMI) of the volunteers ranged from 21 to 30 kg/m2
and their age from 22 to 34 years (Table 1). During the
study, thyrotoxicosis questionnaires were performed as well
as 24 h blood pressure, and pulse rate activity (Cambridge
Nanotechnology, Cambridge, UK) were recorded. The work
has been approved by the ethics committee of the Univer-
sity of Lübeck and written informed consent was received
from all participants prior to the study. The study con-
formed to the WMA Declaration of Helsinki.
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Assays
Serum levels of TSH, free triiodothyronine (FT3) and FT4
were measured using an immunoassay (Dimension
VISTA, Siemens Healthcare Diagnostics, Eschborn,
Germany) with a functional sensitivity of 0.005 mU/L for
TSH, 0.77 pmol/L for FT3, and 1.3 pmol/L for FT4. SHBG
levels were determined via a chemiluminescent enzyme
immunoassay on an Immulite 2000XPi analyzer (SHBG
Immulite 2000, Siemens Healthcare Medical Diagnostics,
Bad Nauheim, Germany) with a functional sensitivity of
0.02 nmol/L. Serum cystatin C (CYTC) was measured
using a nephelometric assay (Dimension VISTA, Siemens
Healthcare Diagnostics, Eschborn, Germany) with a
functional sensitivity of 0.05 mg/L. Insulin serum concen-
trations were measured using a chemiluminescent immu-
nometric assay (Immulite 200 XPi; Siemens Healthcare
Diagnostics) with a functional sensitivity of 2 mU/L.
Lipids (total cholesterol, HDL- and LDL cholesterol, tri-
glycerides), serum glucose, serum activities of alanine
amino transferase (ALT), aspartate amino transferase
(AST), γ-glutamyl transpeptidase (GGT), as well as the
levels of the complement factors C3 and C4 were mea-
sured by standard methods (Dimension VISTA, Siemens
Healthcare Diagnostics, Eschborn, Germany).
Plasma metabolome analysis
Metabolic profiling of plasma samples was performed by
Metabolon Inc. (Durham, NC, USA), a commercial sup-
plier of metabolic analyses. Three separate analytical
methods (GC-MS and LC-MS (positive and negative
mode)) were used to detect a broad metabolite panel
[19]. Briefly, proteins were precipitated from 100 μL
plasma with methanol, which further contained four stan-
dards to monitor extraction efficiency, using an automated
liquid handler (Hamilton ML STAR, Hamilton Company,
Salt Lake City, UT, USA). The resulting extract was
divided into four aliquots; two for analysis by LC, one for
analysis by GC, and one reserve aliquot. Aliquots were
placed briefly on a TurboVap® (Zymark, Sparta, NJ, USA)
to remove the organic solvent. Each aliquot was then
frozen and dried under vacuum. LC-MS analysis was
performed on a LTQ mass spectrometer (Thermo Fisher
Scientific Inc., Waltham, MA, USA) equipped with a
Waters Acquity UPLC system (Waters Corporation,
Milford, MA, USA). Two aliquots were reconstituted
either with 0.1% formic acid (positive mode) or 6.5 mM
ammonium bicarbonate (negative mode). Two separate
columns (2.1 × 100 mm Waters BEH C18 1.7 μm particle)
were used for acidic (solvent A: 0.1% formic acid in H2O,
solvent B: 0.1% formic acid in methanol) and basic (A: 6.5
nM ammonium bicarbonate pH 8.0, B: 6.5 nM ammo-
nium bicarbonate in 98% methanol) mobile phase condi-
tions, optimized for positive and negative electrospray
ionization, respectively. After injection, the samples were
separated in a gradient from 100% A to 98% B. The MS
analysis alternated between MS and data-dependent MS/
MS scans using dynamic exclusion. GC-MS analysis was
performed on a Finnigan Trace DSQ fast-scanning single-
quadrupole mass spectrometer (Thermo Fisher Scientific
Inc., Waltham, MA, USA), equipped with a GC column
containing 5% phenyl residues. The temperature was
ramped between 60 and 340 °C. For electron impact
ionization one aliquot was derivatized under dried
nitrogen using bistrimethyl-silyl-triflouroacetemide. Qual-
ity control of platform performance was achieved by the
use of pooled samples and technical blanks as well as the
addition of non-interfering internal standards to the
samples. Metabolites were identified from LC-MS and
GC-MS spectra by automated comparison with a propri-
etary library, containing retention times, m/z ratios, and
related adduct/fragment spectra of over 1000 standard
compounds measured by Metabolon. To correct for daily
variations of platform performance, the raw area count of
each metabolite was rescaled by the respective median
value of the run day. In total, 380 metabolites could be
identified.
Plasma proteome analysis
Depletion of six highly abundant proteins in plasma was
performed using multi-affinity chromatography (MARS6-
Fig. 1 a Study design including sampling time points as well as duration of levothyroxine (L-T4) treatment. b Boxplots with mean values
(diamonds) of serum TSH (white) and FT4 (grey) for each time point. bas baseline, w4(T4)/w8(T4) 4 and 8 weeks of levothyroxine treatment, w12/
w16 4 and 8 weeks after stopping the application point


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Pietzner et al. BMC Medicine  (2017) 15:6 Page 4 of 18
human, Agilent Technologies, Waldbronn, Germany) in ac-
cordance with the manufacturer’s protocol. After pre-
cipitation of proteins of the non-bound fraction with
trichloroacetic acid (final concentration 15%), the pellet was
re-suspended in 100 μL 8 M urea/2 M thiourea. Protein
concentrations of depleted samples were determined via a
Bradford Assay (Bio-Rad Laboratories, Munich, Germany)
using bovine serum albumin as standard protein. Individual
protein samples (4 μg) were reduced with 2.5 mM dithio-
threitol (60 °C, 1 h), subsequently alkylated with 10 mM
iodoacetamide (37 °C, 30 min), and subjected to proteolytic
cleavage with trypsin (Promega, Madison, WI, USA) using
a trypsin to protein ratio of 1:25 overnight at 37 °C. After
stopping the digestion with 1% acetic acid, samples were
purified with C18 ZipTip® with a loading capacity of 2 μg
(Millipore Cooperation, Billerica, MA, USA). Prior to MS
analysis, desalted peptides were subjected to reverse phase
chromatography. Chromatographic separation of peptides
was done on a nanoAquity UPLC system equipped with a
pre-column (nano Aquity UPLC Trap column, 180 μm×
20 mm, 5 μm) and reverse phase column (BEH130 C18,
100 μm × 100 mm, 1.7 μm) configuration (Waters Cor-
poration, Milford, MA, USA). A 100-min non-linear
gradient of 2–60% ACN in 0.1% acetic acid was run at
a constant flow rate of 0.4 μL/min. Mass spectral data
were recorded on-line on a LTQ-Orbitrap Velos mass
spectrometer (Thermo Electron, Bremen, Germany)
which was operated in a data-dependent acquisition
mode. MS/MS fragmentation was performed by colli-
sion induced dissociation. The recorded LC-MS/MS
raw data were processed using the Refiner MS software
version 7.6.6 (GeneData, Basel, Switzerland) with an
adapted workflow with the following steps: (1) chemical
noise removal, (2) retention time alignment across all
samples, and (3) feature extraction and isotope group
clustering. Data was searched against a human Swis-
sprot/Uniprot database (rel. 2012/08) limited to human
entries with a precursor ion tolerance set to 10 ppm
(0.6 Da for fragment ions) using an in-house MASCOT ser-
ver (rel. 2.3). The carbamidomethylation of cysteine was set
as static modification, methionine oxidation was considered
as dynamic modification. Peptides identified with rank = 1
and an ion score ≥ 20 and identified as unique in the data
set were used for relative quantitation on the level of
summed peptide intensities per protein. MS analyses of all
80 plasma samples revealed 2374 unique peptides repre-
senting 497 human proteins. The mass spectrometry prote-
omics data have been deposited to the ProteomeXchange
Consortium via the PRIDE [20] partner repository with the
dataset identifier PXD004815 and 10.6019/PXD004815.
Statistical analysis
To ensure a median availability of data points on three
time points, only metabolites and proteins with less than
40% missing values were used for the analysis, resulting in
349 metabolites and 437 proteins. Values of metabolite/
protein intensities were log10-transformed. To account for
compliance and intestinal resorption during L-T4 treat-
ment we applied a mixed-effect linear regression model
with serum FT4 concentrations as exposure and metabol-
ite/protein concentrations as outcome. Since the study
considered repeated measurements, serum FT4 was deter-
mined as a fixed effect whereas the study participant was
the random effect in the model. All analyses were adjusted
for baseline age and BMI as well as experimental batch in
case of proteome analyses. To account for multiple test-
ing, we adjusted the P values of the regression analysis by
controlling the false discovery rate (FDR) at 5% [21].
Distributional assumptions were tested visually using QQ-
plots and no obvious violations were observed. Robustness
of the results was assessed by a leave-three-out procedure.
For this purpose, we randomly chose three participants
and excluded them from the analyses. This procedure was
repeated 100 times. Since three participants strikingly dif-
fered in their response to L-T4 regarding their serum ALT
and AST activities, an additional data set was created ex-
cluding them leading to finally 101 distinct subsets of the
data. Subsequently, estimates and FDR values were aver-
aged across the subsamples. Metabolites and proteins with
an average FDR below 0.05 were defined significant. In
consequence, the results presented in this work constitute
the most robust FT4-associated alterations. The functional
classification analysis for significantly altered proteins was
performed using Ingenuity Pathway Analysis software
(Ingenuity Systems, Redwood City, CA, USA). Significance
of the enrichment of altered proteins among functional cat-
egories was assessed by Fisher’s exact test. For every time
point, ratios to the baseline values for each participant were
calculated and plotted as mean log2-fold change.
Sample classification
For classification purposes, samples were divided in two
groups. First, all samples before L-T4 treatment as well as
8 weeks after cessation of treatment were defined as eu-
thyroid. Second, all samples from the two treatment time
points were defined as hyperthyroid. Both assignments
were justified by suppressed serum TSH concentrations in
concordance with elevated serum FT4 (Table 1 and Fig. 1).
In total, 64 samples were used for classification analysis
(time point w12, 4 weeks after stop of treatment, was left
out because of the presence of an intermediate state). To
ensure reproducibility of possible markers, only metabo-
lites/proteins without missing values as well as unambigu-
ous assignment were used, resulting in 201 metabolites
and 207 proteins. Since no independent validation set was
available and to avoid overfitting, we performed a two-
stage cross validation procedure to select a subset of
metabolites/proteins capable of classifying the samples
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using a random forest [22] as classifier (Additional file 1:
Figure S1). A first split was performed to divide samples
in training and validation set (outer loop; repeated 30
times). The resulting training sets were once more parti-
tioned into training and test set (inner loop; repeated 50
times). Based on the last split, a random forest was
trained. Prediction performance was assessed using re-
ceiver operating characteristic (ROC) curves on the in-
dependent test set for the current loop. Variable
importance was assessed by the Gini index [23] for
each feature of the trained forest. Variable importance
of each inner loop were averaged weighted by the area
under the ROC-curves (AUC). The 15 most important
variables from the inner loop were taken forward to
build a new random forest. Analogous to the previous
procedure the prediction performance was assessed
yielding the final classification performance based on a
reduced subset of the features. The random forest was
implemented in R via the randomForest package (v 4.6-
10) [22]. Statistical analyses were performed using SAS
version 9.4 (SAS statistical software, version 9.4, SAS
Institute, Inc.; NC, USA) and R 3.0.1 (R Foundation for
statistical computing, version 3.0.1, Vienna, Austria).
Results and Discussion
L-T4 treatment and standard clinical hormone assays
As previously described [24], treatment with 250 μg/day
L-T4 for 8 weeks resulted in the expected suppression of
mean TSH concentrations from 2.10 mU/L (standard
deviation (SD): ±1.01) at baseline to 0.017 mU/L (SD:
±0.029) at 4 weeks and 0.007 mU/L (SD: ±0.007) at
8 weeks, respectively. Mean concentrations of FT4 and
FT3 exhibited the opposite profile with peak concentra-
tions of 28.6 pmol/L (SD: 5.7) and 9.19 pmol/L (SD:
±2.01) after 4 weeks of L-T4 intake, respectively, consist-
ent with a biochemical condition of overt hyperthyroid-
ism (Fig. 1 and Table 1). All parameters normalized
within the first 4 weeks after termination of L-T4 intake
(Fig. 1b). We further assessed effects on some of the
well-known TH targets such as SHBG, CYTC, and dif-
ferent blood lipids (Table 1). In general, L-T4 treatment
resulted in a transient decline of blood lipids (Fig. 2)
apart from triglycerides, whereas serum glucose and in-
sulin were not significantly altered. The complement fac-
tors C3 and C4 showed a moderate, but significant
positive association with FT4 (Fig. 2).
General FT4-associated alterations of the plasma
metabolome
Treatment of the euthyroid male volunteers with L-T4
markedly affected the plasma metabolome, significantly
altering the levels of 65 out of 349 detected metabolites
(19%), of which 45 exhibited a positive and 20 a negative
association with serum FT4, respectively. The associated
metabolites represented diverse metabolite classes,
where lipids and related compounds encompassed the
largest portion of FT4-associated molecules (39 of 65
Fig. 2 Means with 95% confidence intervals for serum concentrations of selected biochemical parameters during the study periods. Corresponding
estimates from regression analyses are given in Table 1. bas baseline, w4(T4)/w8(T4) 4 and 8 weeks of levothyroxine treatment, w12/w16 4 and 8 weeks
after stopping the application
Pietzner et al. BMC Medicine  (2017) 15:6 Page 6 of 18
present in the analysis panel). These could be
assigned to the following categories: free fatty acids
(FFAs), acyl carnitines (ACs), polyunsaturated fatty
acids (PUFAs), lysophospholipids (LPs), and andro-
gens. All results are summarized in Fig. 3 and
Additional file 2: Table S1.
Fig. 3 Heatmap of plasma metabolites significantly associated with free thyroxine (FT4) in mixed effect linear regression models. The first column
displays the values of the mean false discovery rate (FDR) for the FT4 effect across 101 subsamples coded in grey color. The other columns indicate the
mean log2-ratio from baseline (bas) compared to 4 (w4(T4)) and 8 (w8(T4)) weeks of treatment as well as 4 (w12) and 8 (w16) weeks after finishing the
treatment. The time course of the FT4 concentrations is shown on top of the map as reference. Orange shading denotes an increase and blue shading
a decrease compared to baseline, respectively. Derived physiological signatures are labeled on the left. The corresponding estimates and FDR values
from regression analysis can be found in Additional file 2: Table S1. Metabolites marked with a star were assigned based on in silico
fragmentation spectra
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A plasma metabolome signature indicating increased
resting energy expenditure and enhanced mitochondrial
fatty acid β-oxidation
Thyroxine treatment induced an increase in long chain
saturated as well as monounsaturated FFAs, which was
accompanied by elevated glycerol levels (Fig. 3). As dem-
onstrated by Mitchell et al. [25], both Graves’ thyrotoxi-
cosis and resistance to TH due to THRB mutations
(RTHβ) result in significantly increased resting energy
expenditure. Involved mechanisms include TH-stimulated
lipolysis in white adipose tissue, mediated by increased
local concentrations of catecholamines with successive
activation of adipocyte β-adrenergic receptors [26, 27].
Consistently, the ubiquitous increase of FFAs and glycerol
in plasma following L-T4 treatment observed in the
present study clearly indicates TH-triggered lipolysis in
white adipose tissue.
After transport into tissues highly active in respiration,
namely skeletal muscle as the major determinant of energy
expenditure in humans [28], and liver, FFAs are subjected
to mitochondrial β-oxidation that is also enhanced by TH.
This is mainly mediated by increased expression of CPT1
encoding carnitine palmitoyltransferase-I (CPT-1), which
represents a direct transcriptional target of T3-activated
TR [29]. In exchange with carnitine, acyl-carnitines are
translocated through the outer mitochondrial membrane
by CPT-1 [30]. Simultaneous TH-mediated up-regulation
of the gene encoding the final enzyme of carnitine biosyn-
thesis, the γ-butyrobetaine hydroxylase, ensures the in-
creased carnitine levels required for that, as demonstrated
in a rodent model [31]. The resulting enhanced activity of
the complete carnitine acyl-carnitine translocase system
explains the pronounced increase in short to medium
chain ACs in plasma observed in this study (Fig. 3), as a
fraction of the newly synthesized ACs spills from tissue in
the circulation, as reported earlier by Jourdan et al. [32].
Indeed, our results replicate the positive association be-
tween ACs and FT4 reported by this group for the
population-based KORA cohort study based on data from
1463 euthyroid individuals [32]. In contrast, a previous
patient-based study revealed no relation between plasma
AC profiles and the restoration of euthyroidism [33]. How-
ever, the value of the latter results might be limited by the
small sample size of six hyper- and hypothyroid individ-
uals, respectively.
Augmented β-oxidation of FFAs causes increased
acetyl-CoA levels and stimulation of the TCA cycle, which
would be expected to finally trigger increased ATP pro-
duction by oxidative phosphorylation. Indeed, accelerated
carbon flux through the TCA cycle was demonstrated in
human skeletal muscle in a short-term model of experi-
mental thyrotoxicosis (Lebon et al. [34]) as well as in pa-
tients suffering from RTHβ (Mitchell et al. [25]). However,
ATP production by oxidative phosphorylation did not
change under these conditions, which was explained by
increased uncoupling of respiration and ATP synthesis,
potentially caused by increased expression of UCP3
(SLC25A9) encoding the mitochondrial uncoupling pro-
tein 3 (Lebon et al. 2001; Mitchell et al. [25]). Less efficient
ATP generation in muscle might also explain our observa-
tion of increased creatine plasma levels (Fig. 2) under con-
ditions of thyrotoxicosis, as the synthesis of the central
muscle energy storage compound phosphocreatine by
ATP-dependent creatine phosphorylation can be predicted
to be reduced by TH-induced mitochondrial uncoupling.
Enhanced systemic glucose utilization represents a fur-
ther well-known consequence of increased energy expend-
iture under conditions of hyperthyroidism [29]. In the liver,
TH stimulate glycogenolysis and gluconeogenesis mainly
consuming gluconeogenic amino acids and glycerol while
down-regulating glycolysis, resulting in a higher hepatic
glucose output [35]. In this context, the already mentioned
strongly increased plasma glycerol pool under L-T4 treat-
ment that is explained by stimulated lipolysis also repre-
sents a potential source for gluconeogenesis (Fig. 3). Our
did not support for the use of amino acids as a source for
TH-stimulated hepatic gluconeogenesis, partially in line
with results of the already mentioned population-based
KORA study [32]. However, the unaltered plasma levels of
gluconeogenic amino acids that were measured despite the
predicted increased demand after L-T4-treatment could be
caused by the enhanced renal amino acid recovery reported
for such conditions [36].
In skeletal muscle, TH induce expression of SLC2A4 en-
coding the glucose transporter GLUT4 as well as traffick-
ing of GLUT4 to the plasma membrane [29]. Thus,
increased glucose uptake in peripheral tissues, namely the
muscle, might explain our observation that in spite of
increased hepatic glucose release the corresponding serum
concentrations were not significantly changed (Table 1).
However, besides glucose, glycogenolysis also produces
glucose-6-phosphate which subsequently can be con-
verted to mannose [37]. Whether the increased plasma
mannose levels observed in our study (Fig. 3) reflect TH-
stimulated glycogenolysis in liver or result from glycogen
breakdown in muscle remains unclear.
A plasma metabolome signature indicating augmented
defense against systemic oxidative stress
The strong positive FT4-association observed for γ-
glutamyl amino acid (GGAA) levels represents one of the
novel findings of this study (Fig. 3). As elevated GGAA
levels were recently related to several types of liver damage
[38] and TH were furthermore demonstrated to represent
potent hepatic mitogens triggering hepatocyte turnover
[39], we first hypothesized that the observed increase dur-
ing thyrotoxicosis might also result from hepatocellular
lysis. However, determination of the classical laboratory
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markers for liver damage, namely ALT, AST, and GGT
activities in serum, did not support this hypothesis.
GGAA synthesis by transfer of the glutathione (GSH)
glutamyl moiety to free amino acids is catalyzed by γ-
glutamyl transpeptidase (GGT) as part of the γ-glutamyl
cycle (GGC). As the GGT catalytic center is localized at the
extracytoplasmic side of the hepatocyte membrane, this
represents the site of γ-glutamyl amino acid production,
which is strongly determined by the availability of GSH
[40]. The rate-limiting step in GSH biosynthesis is catalyzed
by the heterodimeric glutamate-cysteine ligase consisting of
a heavy catalytic and a light regulatory subunit. Expression
of GCLC and GCLM encoding the two subunits of the en-
zyme is induced by transcriptional up-regulation via NRF2,
the redox-sensitive key regulatory transcription factor of
the major cellular defense system against oxidative stress
[41]. Strikingly, hepatic activation of the NRF2 regulon by
TH-induced production of reactive oxygen species due to
increased respiration was demonstrated in rodent models
[42, 43]. Similarly, a stimulatory effect of TH on the GGC
resulting in improved antioxidant capacity was shown in
astrocytes [44]. Thus, it seems plausible that the increase in
plasma GGAA levels under conditions of thyrotoxicosis
observed in this study reflects the NRF2-mediated induc-
tion of GSH synthesis as part of the systemic network an-
tagonizing pronounced oxidative stress as a consequence of
FT4-stimulated respiration.
Our study further revealed an FT4-associated increase in
n3 and n6 plasma PUFAs and a drop in LPs (Fig. 3), par-
tially replicating findings from other recent metabolome
analyses [17, 32, 45]. Indeed, the LPs displayed opposite
associations, depending on the presence of either choline
(lysophosphatidylcholine (LPC); positively associated) or
ethanolamine (lysophosphatidylethanolamine (LPE); nega-
tively associated) as the head group (Fig. 3).
Previous animal studies demonstrated a direct negative
effect of TH on the hepatic PUFA content [46–48], wherein
PUFAs were depleted under hyperthyroid conditions. It
was supposed that TH initiate remodeling of mitochondrial
membranes resulting in a decrease of PUFA-containing
phosphatidylcholines. As saturated FAs are less prone to
peroxidation, this was interpreted as an adaptive mechan-
ism contributing to the protection of mitochondrial
membranes against enhanced oxidative stress forced by
TH-induced up-regulation of respiration [46, 47]. Thus,
PUFA release from mitochondrial membranes might be
reflected in the observed increased plasma PUFA levels.
The negative association between serum FT4 and plasma
LPEs represents an additional novel finding of this study
(Fig. 3). Previous analyses of rodent hyperthyroidism
models [49, 50] revealed enhanced incorporation of phos-
phatidylethanolamine (PE) in mitochondria of liver [50] and
brain [49]. Augmented PE utilization might explain the ob-
served plasma decrease of PE metabolites, namely the LPEs.
Discordant changes in classical and novel markers of
kidney function under thyrotoxicosis
As outlined above, increased plasma creatine levels under
conditions of thyrotoxicosis most likely reflect decreased
creatine phosphorylation in skeletal muscle due to pro-
nounced uncoupling of respiration and ATP synthesis. By
contrast, we observed decreased plasma levels of the creat-
ine catabolite creatinine in this study (Fig. 3), which could
be explained by increased renal clearance of creatinine,
possibly above the general glomerular filtration rate [51].
Both findings were previously described for hyperthyroid-
ism [52, 53]. Thus, a reliable estimation of the glomerular
filtration rate based on creatinine might be biased and ham-
pers the interpretation of kidney function in thyroid disease.
Similar holds true for CYTC, the second common circulat-
ing marker for kidney function, which was strongly elevated
by L-T4 treatment in our study, a finding in line with
previous results of hyperthyroidism studies [54, 55]. Very
recently, novel promising markers for kidney function esti-
mation were published using a similar metabolomics ap-
proach as in this study [56], namely C-mannosyltryptophan
and pseudouridine. In contrast to creatinine and CYTC,
none of these markers was altered to a similar extent in the
present study (Additional file 2: Table S1), suggesting that
the observed changes in creatinine and CYTC levels are
metabolically driven and to a lesser extent due to altered
kidney function. Thus, novel markers of kidney function
such as C-mannosyltryptophan and pseudouridine may be
advantageous under conditions of thyrotoxicosis.
Thyrotoxicosis increases plasma asymmetric
dimethylarginine (ADMA) levels
We observed increased plasma levels of methylated argin-
ine (as the sum of ADMA and symmetric dimethylarginine)
under L-T4 treatment, while the levels of its catabolite cit-
rulline decreased (Fig. 3). A positive association between
TH levels and circulating ADMA was previously reported
in epidemiological studies and under conditions of hyper-
thyroidism [57–60]. ADMA was suggested as a severe risk
factor for cardiovascular disease (for review see [61]),
mainly as it directly inhibits endothelial nitric oxide
synthase (NOS), thereby impairing NO-dependent
vasodilation and favoring hypertension. ADMA is gen-
erated as a putative by-product of pronounced systemic
proteolysis [62], which is known to be triggered by TH
excess [63]. Therefore, the increased plasma levels of
leucine, isoleucine, and their degradation intermediate
2-methylbutyrylcarnitine in the present study (Fig. 3)
might indicate pronounced FT4-associated protein
catabolism. The products of dimethylarginine
dimethylaminohydrolase-catalyzed ADMA degradation,
citrulline, and dimethylamine, are subsequently cleared
by the kidneys [64]. At least one study using a murine
model [65] described an inhibitory effect of prolonged
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T3 treatment on dimethylarginine dimethylaminohy-
drolase in the liver. Thus, our novel observation of an
FT4-associated ADMA/symmetric dimethylarginine in-
crease and citrulline decrease in plasma may indicate
TH-induced suppression of ADMA catabolism leading
to its systemic accumulation. In sum, augmented pro-
duction as well as reduced decomposition of ADMA
might therefore contribute to its increased plasma
levels under conditions of thyrotoxicosis.
Thyrotoxicosis-induced elevated ADMA levels are pre-
dicted to mediate increased blood pressure by NOS inhib-
ition [57–59]. The notion that TH directly affect vascular
smooth muscle cells causing vascular relaxation and
dilatation [66, 67] seemingly contradict the above dis-
cussed findings. However, it appears that the described
TRα-dependent, non-genomic activation of endothelial
NOS via the PI3/AKT-pathway is only present at very high
TH concentrations [68, 69], which were not observed in
the present study.
General FT4-associated alterations of the plasma proteome
Using an untargeted shotgun-LC-MS/MS-approach, our
proteome study demonstrated two major general categories
of proteins exhibiting FT4-associated plasma levels, namely
the higher abundant actively secreted proteins predomin-
antly originating from the liver and representing the major-
ity of detected proteins and, in addition, leakage proteins
whose presence in the circulation is predicted to result
from cell lysis. The latter comprised only 3% of the total
protein intensity. Similar to the metabolome, the levels of
63 out of 437 detected proteins (14%) exhibited significant
associations with FT4 (Additional file 2: Table S2). The
majority (N = 47) was positively associated, whereas about
one fourth (N = 16) demonstrated a negative association
with serum FT4. SHBG and CYTC, which are known to be
altered in thyroid dysfunction, were among the strong
positively FT4-associated proteins. The changes in the levels
of both proteins as determined by MS were similar to those
measured with standard laboratory assays (Additional file 1:
Figure S3). Of note, we observed no significant alterations
of the major TH transport proteins thyroxine-binding
globulin (SERPINA7) and thyroid-hormone binding protein
transthyretin. The results are summarized in Fig. 4 and
Additional file 2: Table S2.
A plasma proteome signature indicating decreased
lipoprotein particle levels during thyrotoxicosis
TH-dependent alterations in the levels of apolipoproteins
and different lipid-rich particles were reported previously
[70–73]. In line with these findings, we observed a signifi-
cant drop in the plasma levels of apolipoproteins APOB
(apoB-100), APOD, and APOC3 (apoCIII) during the peak
of induced thyrotoxicosis, where APOD exhibited the
strongest association (Fig. 4 and Additional file 2: Table S2).
The apoB100 protein represents the primary apolipo-
protein of VLDL and LDL particles essentially mediating
systemic transport of lipids including cholesterol to per-
ipheral tissues in the context of the fuel and overflow
transport pathways, respectively, and is the primary ligand
of the low-density lipoprotein receptor (LDL-R) [74].
Peripheral as well as liver-specific LDL particle uptake via
apoB100-dependent LDL-R binding and endocytosis is
promoted by TH, as LDLR encoding this receptor rep-
resents a direct TR target and is additionally up-
regulated by the transcriptional regulator SREBP-2,
which, in turn, is also induced by TH at the gene ex-
pression level [75–77]. Thus, the decreased apoB100
abundance under conditions of thyrotoxicosis repre-
sents a direct consequence of TH-stimulated LDL up-
take from the circulation.
APOD is primarily associated with HDL particles medi-
ating reverse cholesterol transport (RCT) from peripheral
tissues to the liver. It represents an atypical apolipoprotein
and belongs to the family of lipocalin proteins which
transport small hydrophobic ligands [78]. TH stimulate
the RCT by increasing the expression of several genes
involved in cholesterol metabolism, among them SCARB1
encoding the multiple-ligand binding scavenger receptor
class B member 1 (SRB1), which is responsible for the
binding of cholesterol enriched HDL particles in numer-
ous cell tissues, namely liver and adrenal [79]. Therefore,
the observed drop in APOD plasma levels can be ex-
plained by TH-stimulated HDL particle binding as part of
the activated RCT.
The apoCIII protein is localized on the surface of mature
triglyceride-rich chylomicrons and VLDL particles as well
as HDL particles contributing to the fuel transport and the
RCT pathways, respectively [74]. Uptake of VLDL particles
is mediated by the VLDL receptor that binds APOE, a fur-
ther apolipoprotein found in chylomicrons. Expression of
the gene encoding this receptor was demonstrated to be
under positive TH control in a rodent model [80]. There-
fore, the decreased apoCIII levels observed in our study
during thyrotoxicosis are explained by TH-mediated up-
regulation of the genes encoding VLDL receptor and SRB1.
The TH-induced drop in the plasma levels of apolipo-
proteins belonging to different classes is consistent with
the observed significant TH-associated transient reduc-
tions in the plasma levels of HDL-cholesterol, LDL-
cholesterol, and total cholesterol as determined by
standard clinical assays (Table 1 and Fig. 2).
A plasma proteome signature indicating augmented
coagulation during thyrotoxicosis
The positive association between blood coagulation and
TH concentrations is well known. In line with the pre-
dominantly clinical studies published so far on this topic
[81–85], our proteome analysis demonstrated several
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proteins involved in the coagulation cascade to exhibit
FT4-associated plasma levels (Fig. 4); these findings have
been published separately [86]. In short, we were able to
demonstrate that experimental thyrotoxicosis increases
the levels of coagulation cascade proteins in plasma,
supporting a positive impact of TH on blood coagulation
even at non-pathological levels. Coagulation factor XIII
B chain (F13B) and the factors IX (FA9) and XI (FA11)
Fig. 4 Heatmap of plasma proteins significantly associated with free thyroxine (FT4) in mixed effect linear regression models. The first column
displays the values of the mean false discovery rate (FDR) for the FT4 effect across 101 subsamples of the data coded in grey color. The other
columns indicate the mean log2-ratio from baseline (bas) compared to 4 (w4(T4)) and 8 (w8(T4)) weeks of treatment as well as 4 (w12) and 8
(w16) weeks after finishing the treatment. The time course of FT4 concentrations is shown on the top of the map as reference. Orange shading
denotes an increase and blue shading a decrease compared to baseline, respectively. Derived physiological signatures are labeled on the left.
The corresponding estimates and FDR values from regression analysis can be found in Additional file 2: Table S2
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exhibited significantly increased levels under thyrotoxi-
cosis conditions, as well as SERPINA5 (IPSP), an inhibi-
tor of activated protein C. As the latter inhibits clot
formation, increased levels of its inhibitor SERPINA5
and of factors XIIIB, IX, and XI can be predicted to re-
sult in a prothrombotic, hypercoaguable environment, in
accordance with the aforementioned findings from
clinical studies [81–85]. For factors XIIIB and IX, the in-
creased plasma levels after L-T4-treatment were inde-
pendently validated by ELISA techniques [86]. The
molecular mechanism(s) underlying the increased levels
of these proteins are currently not clear and cannot be
clarified by our study design. Plausible hypotheses might
be a TH-stimulated increase of their stability in plasma
or enhanced expression of their encoding genes. The
recently published finding of unaltered coagulation
parameters in RTHβ patients despite elevated FT4
levels favors the latter hypothesis and suggests that the
procoagulant effects observed under conditions of
thyrotoxicosis and hyperthyroidism are mediated via
TRβ [87].
A plasma proteome signature indicating increased
complement system plasma protein levels
Nine proteins of the complement system were positively
associated with FT4, including mannose-binding protein
C (MBL2) and mannan-binding lectin serine protease 2
(MASP2). Additionally, the complement-factor H-related
proteins CFHR1 and CFHR5 as binding proteins of com-
plement component C3b showed a positive association
with serum FT4 (Fig. 4). Consistently, although the C3
protein barely missed statistical significance in the prote-
ome analysis (Additional file 2: Table S2), higher abun-
dance of C3 as well as C4 was determined by standard
laboratory assays (Table 1 and Fig. 2). In addition, our me-
tabolome analysis detected one C3 fragment (HWE-
SASLLR) [88] mirroring the positive association (Fig. 3).
Similarly, clinical studies [84, 89, 90] reported positive as-
sociations between complement system proteins and TH
levels. Of note, the duration of hyperthyroidism might be
crucial in this context, since a short-term model of experi-
mental thyrotoxicosis revealed no significant C3 level
alterations [84]. Data explaining the impact of TH on the
complement system proteins, which originate primarily
from the liver, are scarce. Previous studies demonstrated
that MBL2 encoding mannose-binding lectin, an early
module of the lectin pathway in the complement system
that exhibited increased plasma levels under thyrotoxi-
cosis conditions in our study, represents a direct PPARα
target [91, 92]. As PPARα belongs to those transcriptional
co-regulators interacting with TH-ligated TR [29], it may
be speculated that a corresponding TH-mediated
induction ofMBL2 expression causes the observed plasma
level increase, which might also hold true for other
complement system proteins. However, in mice, the fact
that several analyses of the hepatic transcriptome in differ-
ent murine models before and after T3 application failed
so far to demonstrate convincingly differentially expressed
genes encoding complement system proteins [65, 93–95]
argues against a TR-dependent regulation at the mRNA
level. Future analyses involving TH-treated primary
human hepatocytes might represent a promising approach
to clarify the molecular mechanism(s) underlying the ob-
served plasma level alterations of complement system
proteins.
Differences in response profiles and effect magnitudes
Different kinetic patterns as well as mean magnitude sizes
were observed for several associated molecule categories
(Figs. 3 and 4): ACs exhibited an invariable response during
the complete study period whereas the levels of long-chain
FAs further increased between 4 and 8 weeks (Fig. 3). In
contrast, complement system proteins reached their max-
imal mean levels after 4 weeks of L-T4 treatment followed
by a moderate decline after 8 weeks (Fig. 4). Time-
dependent alterations were also evident in the magnitudes
of the detected effects. For instance, lipid species demon-
strated an almost two-fold increase, whereas the levels of
complement system proteins increased only moderately
(~30%). Despite these differences, all associations were
most likely mediated by L-T4 treatment as they were cap-
tured by the mixed-effect linear regression models.
A biomarker-based signature to predict thyroid function
Our approach of a precisely controlled transient increase in
systemic TH levels in healthy male volunteers allowed
characterizing effects clearly and unambiguously based on a
defined duration and dose of thyroxine. As we deliberately
searched for a clinically relevant and yet unmet diagnostic
approach to classify TH status without using TSH and/or
free TH, we combined the data generated by the untargeted
OMICS techniques in a classification model. For this pur-
pose, we built a random forest classifier via a two-stage
cross-validation procedure (see Methods and Additional file
1: Figure S1), thereby allowing for a more realistic estima-
tion of the generalization of the random forest than
conventional k-fold cross-validation. This is exemplarily
demonstrated by the ROC curves (Fig. 5), which were
obtained when both situations occurred, perfect (AUC= 1)
as well as fair (AUC= 0.75) classification neither represent-
ing the expected general performance. Additionally, the ap-
proach chosen here allowed for combining classification
with feature selection to define a small set of biomarkers
among the numerous FT4-associated molecules described
above. We obtained a list comprising 15 metabolites and
proteins (Fig. 5, left panel) exhibiting robust and good clas-
sification performance over all 30 validation runs (mean
AUC= 0.86; Fig. 5, right panel) and therefore representing
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appropriate biomarkers for a reliable prediction of the TH
status. Of this biomarker panel, most components were
already discussed above in the context of different physio-
logical signatures, namely increased resting energy expend-
iture and enhanced mitochondrial fatty acid β-oxidation
(decanoylcarnitine, octanoylcarnitine, hexanoylcarnitine,
laurylcarnitine), increased GSH synthesis as part of the aug-
mented defense against oxidative stress as a consequence of
stimulated respiration (γ-glutamylvaline, γ-glutamylleucine,
γ-glutamylmethionine), and increased levels of complement
system (FHR5) or coagulation (F13B) proteins.
Cadherin-5 (CDH5), also named VE-cadherin, represents
a calcium-dependent adhesion protein specific to endothe-
lial cells and is a major component of adherens junctions
found in blood vessels. It is essentially involved in the
regulation of vascular integrity, restricting permeability of
the endothelium [96]. Shedding of CDH5 by proteinases in-
creases microvascular permeability and is one of the mo-
lecular mechanisms involved in transendothelial neutrophil
migration during inflammatory processes and endothelial
apoptosis [97]. CDH5 shedding is mediated by two protein-
ases of the ADAM (A Disintegrin And a Metalloprotease
domain metalloproteases) family, namely ADAM9 and
ADAM10 [98], where the proteolytic activity of ADAM10
is stimulated by thrombin (coagulation factor 2, F2a) [99].
Therefore, the observed increased levels of circulating
CDH5 most probably result from stimulated thrombin acti-
vation under the prothrombotic thyrotoxicosis-associated
conditions described above.
A similar explanation can be found for the increased
vasorin (VASN) levels – VASN is a typical type I mem-
brane protein that was identified as target of the ADAM17
metalloprotease. Limited proteolysis by ADAM17 gener-
ates a soluble fragment encompassing the extracellular
VASN domain, which directly binds to transforming
growth factor (TGF)β and attenuates TGFβ signaling
[100]. As in the case of ADAM10, ADAM17-dependent
shedding has been demonstrated to be stimulated by
thrombin [101]. Consistently, the three CDH5-specific
peptides as well as the six VASN-specific peptides that
were detected in the proteome analysis exclusively
mapped to the extracellular domains of the two proteins.
Therefore, together with CFHR5, CDH5, and VASN can
be assigned to the signature of increased levels of coagula-
tion factors.
The plasma level of cysteine was previously reported to
be decreased by TH-treatment via direct down-regulation
of the expression of CTH and CBS encoding cystathionine
gamma-lyase and cystathionine beta-synthase, respectively
[102]. This might explain the pronounced negative associ-
ation between the plasma levels of cysteine as well as its
metabolite 4-amino-2-hydroxybutyrate and FT4 in our
Fig. 5 Final results from classification analyses using random forests in a two-stage cross-validation scheme with 50 inner and 30 outer loops
(Additional file 1: Figure S1). Left panel: Fifteen most important metabolites/proteins ranked by a weighted (area under the curve) mean Gini
index. Right panel: Receiver operating characteristic (ROC) curves (upper) and boxplot of the area under the curve (lower) from 30 outer loops.
Overlapping ROCs are displayed by darker shades and the diamond indicates the mean AUC. CADH5 cadherin-5, FHR5 complement factor
H-related protein 5, F13B coagulation factor XIII B chain, LUM lumican, VASN vasorin
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study (Fig. 3). Threonate, which is either derived from gly-
cated proteins or represents a degradation product of
ascorbate [103], was previously linked to altered thyroid
function in two murine models [45, 104], but not yet in
humans.
Finally, lumican (LUM) represents an extracellular matrix
protein modified as a proteoglycan in several tissues. The
core protein with leucine-rich repeats that are characteristic
for the corresponding superfamily binds collagen fibrils and
regulates its structure. In addition, LUM associates with
CD14 on the surface of macrophages and neutrophils and
promotes the CD14-TLR4 mediated response to bacterial
lipopolysaccharides where it is involved in macrophage-
mediated phagocytosis [105–107]. LUM is proteolytically
degraded by matrix metalloproteinase (MMP) 14 [108],
whose encoding gene MMP14, among several other genes
encoding MMPs, was demonstrated to be down-regulated
by TH [109]. Thus, the observed increase in plasma LUM
levels might be the consequence of its decreased degrad-
ation due to TH-mediated reducedMMP14 expression.
Conclusion
The unique feature of the present study is its specific experi-
mental design. By focusing on healthy young male volunteers
we excluded any potentially interfering, disease-specific influ-
ences related, for example, to the autoimmune process in
Graves’ thyrotoxicosis. This approach allows to control the
extent and duration of biochemical hyperthyroidism induced
by thyroxine as one of the most prescribed drugs and to
monitor its recovery, thereby enabling unique insights into
the kinetics of subjective changes experienced by the volun-
teers in relation to the biochemical changes measured.
Application of L-T4 clearly induced biochemical thyro-
toxicosis in our volunteer sample as indicated by strongly
suppressed TSH and clearly increased TH levels, which
were rapidly reversed after ceasing hormone application.
The model was further validated by known thyrotoxic al-
terations in biochemical markers, including SHBG, CYTC,
and total and LDL-cholesterol [12, 13, 55].
Interestingly, as described in a previous study analyz-
ing the same volunteer sample, subjectively the volun-
teers did not notice any thyrotoxic symptoms, which
was supported by the negative results of a standardized
questionnaire for thyrotoxicosis and a battery of behav-
ioral and cognitive tests [24]. A 24-h blood pressure pro-
file before and at the end of 8 weeks of thyroxine
application was not significantly different, neither when
analyzed over 24 h or during sleep between 01:00 and
06:00 am [24]. In contrast, comparison of the mean 24-h
pulse rates revealed a moderate increase of about 8.9
beats/minute (from 66.7 to 75.6 beats/minute), which
was not recognized by the volunteers [24].
L-T4 application clearly changed a large number of bio-
chemical parameters beyond the expected alterations in
TSH and TH levels or in known biochemical markers. The
combined findings reveal a surprising discrepancy between
biochemical alterations and subjective symptoms in this co-
hort of young healthy subjects and shed new light on the
mechanisms mediating adaptation to subclinical hyperthy-
roidism. They suggest that biochemical alterations might be
detectable considerably earlier than clinical symptoms
occur and are much more sensitive. In consequence, the
diagnosis of thyrotoxicosis in clinical routine might fre-
quently miss the real onset time of the disease by several
months.
The comprehensive robust analysis of a human thyrotoxi-
cosis model using state of the art untargeted plasma
OMICS approaches demonstrated a strong and pleiotropic
metabolic impact of TH on this compartment. The charac-
terized physiological signatures comprised biomarkers indi-
cating increased resting energy expenditure, augmented
defense against systemic oxidative stress, decreased lipopro-
tein particle levels, and increased levels of complement sys-
tem proteins as well as coagulation factors, where the latter
results in a pro-thrombotic environment. Measurement of
15 specific biomarkers, metabolites as well as proteins,
allowed reliable prediction of the individual thyroid func-
tion in the analyzed sample independent of common TSH
and FT4 measurements. In addition, by following the sub-
jects during the recovery from thyrotoxicosis we gained
first insight in the target-specific kinetics of TH-dependent
responses. The definition of this prediction panel might
represent an important step forward in molecular
characterization of early forms of hyperthyroidism.
However, it has to be emphasized that the analyzed study
sample consisted exclusively of young men, limiting the
generalizability of the results. Therefore, further validation
studies using larger samples of higher complexity in terms
of age and sex as well as hypothyroid conditions have to be
performed. Similarly, our findings concerning the influence
of increased TH levels on kidney function markers and
systemic ADMA levels that might be of special clinical
importance have to be replicated in appropriate patient co-
horts and/or population-based studies where the required
parameters are available.
Additional files
Additional file 1: Figure S1. Flowchart of the classification procedure.
Each outer loop started with splitting off the validation data from the
remaining data that were further divided in a training set and a test set at
each start of a training period. The training set was used to build a random
forest (RF) exploiting all metabolites/proteins as features. Predictions were
made on the test set and RF performance was assessed by the area under the
curve (AUC) while feature importance was measured as the Gini index.
Training was repeated on i different splits of data and an AUC-weighted mean
Gini index was computed for all features. Afterwards, a new RF restricted to
the top k features (those with the highest mean Gini index) was built. It was
trained on the combination of training and test data and employed to classify
the validation data. The described procedure was repeated j-times, once more
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yielding an AUC-weighted mean Gini index for feature importance. The final
results of this procedure with i = 50, j = 30 and k = 15 are shown in Fig. 4 in
the main text. Figure S2. Boxplots for each study time point for glucose and
total cholesterol levels measured either by standard laboratory assays (dark
grey) or by metabolomics (light grey). bas baseline, w4(T4)/w8(T4) 4 and
8 weeks of levothyroxine treatment; w12/w16 4 and 8 weeks after stopping
the application. Figure S3. Boxplots for each study time point for sexhor-
mone- binding globulin (SHBG) and cystatin C levels determined either by
standard laboratory assays (dark grey) or in the untargeted proteome ap-
proach (light grey). bas baseline, w4(T4)/w8(T4) 4 and 8 weeks of levothyroxine
treatment, w12/w16 4 and 8 weeks after stopping the application. (DOCX 580
kb)
Additional file 2: Table S1. Results from mixed-effect linear regression
analyses with serum FT4 concentrations as exposure and metabolites as
outcome. Table S2. Results from mixed-effect linear regression analyses
with serum FT4 concentrations as exposure and protein levels as
outcome. (XLSX 88 kb)
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